Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group.

NCT00180115 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT00180115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00180115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group.
Lead sponsor
Technische Universität Dresden
Phase
Phase 4
Overall status
Completed
Start date
February 29, 1996
Completion date
November 30, 2008
Enrollment
400
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, nonlymphoblastic, acute